

# Giorgio Valabrega

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/212515/publications.pdf>

Version: 2024-02-01

73  
papers

2,015  
citations

279487

23  
h-index

264894

42  
g-index

75  
all docs

75  
docs citations

75  
times ranked

3480  
citing authors

#	ARTICLE	IF	CITATIONS
1	Outcome of Patients with HER2-Positive Advanced Breast Cancer Progressing During Trastuzumab-Based Therapy. <i>Oncologist</i> , 2006, 11, 318-324.	1.9	116
2	Ovarian Cancer Immunotherapy: Turning up the Heat. <i>International Journal of Molecular Sciences</i> , 2019, 20, 2927.	1.8	116
3	TGF $\beta$ expression impairs Trastuzumab-induced HER2 downregulation. <i>Oncogene</i> , 2005, 24, 3002-3010.	2.6	113
4	PARP Inhibitors in Ovarian Cancer. <i>Recent Patents on Anti-Cancer Drug Discovery</i> , 2018, 13, 392-410.	0.8	102
5	Lapatinib: a dual inhibitor of EGFR and HER2 tyrosine kinase activity. <i>Expert Opinion on Biological Therapy</i> , 2007, 7, 257-268.	1.4	96
6	Checkpoint inhibitors in endometrial cancer: preclinical rationale and clinical activity. <i>Oncotarget</i> , 2017, 8, 90532-90544.	0.8	89
7	Overcoming endocrine resistance in metastatic breast cancer: Current evidence and future directions. <i>World Journal of Clinical Oncology</i> , 2014, 5, 990.	0.9	87
8	Immuno-Metabolism and Microenvironment in Cancer: Key Players for Immunotherapy. <i>International Journal of Molecular Sciences</i> , 2020, 21, 4414.	1.8	87
9	Moderate Immunohistochemical Expression of HER-2 (2+) Without <i>HER-2</i> Gene Amplification Is a Negative Prognostic Factor in Early Breast Cancer. <i>Oncologist</i> , 2012, 17, 1418-1425.	1.9	79
10	Multitarget drugs: the present and the future of cancer therapy. <i>Expert Opinion on Pharmacotherapy</i> , 2009, 10, 589-600.	0.9	66
11	Olaparib as maintenance therapy in patients with BRCA 1-2 mutated recurrent platinum sensitive ovarian cancer: Real world data and post progression outcome. <i>Gynecologic Oncology</i> , 2020, 156, 38-44.	0.6	62
12	Hormone-receptor expression and activity of trastuzumab with chemotherapy in HER2-positive advanced breast cancer patients. <i>Cancer</i> , 2012, 118, 17-26.	2.0	58
13	Endometrial Cancer Stem Cells: Role, Characterization and Therapeutic Implications. <i>Cancers</i> , 2019, 11, 1820.	1.7	57
14	Immune Checkpoint Inhibitors in Epithelial Ovarian Cancer: An Overview on Efficacy and Future Perspectives. <i>Diagnostics</i> , 2020, 10, 146.	1.3	56
15	Immune Checkpoint Inhibitors: A New Opportunity in the Treatment of Ovarian Cancer?. <i>International Journal of Molecular Sciences</i> , 2016, 17, 1169.	1.8	53
16	Differences in PARP Inhibitors for the Treatment of Ovarian Cancer: Mechanisms of Action, Pharmacology, Safety, and Efficacy. <i>International Journal of Molecular Sciences</i> , 2021, 22, 4203.	1.8	49
17	HER2-positive breast cancer cells resistant to trastuzumab and lapatinib lose reliance upon HER2 and are sensitive to the multitargeted kinase inhibitor sorafenib. <i>Breast Cancer Research and Treatment</i> , 2011, 130, 29-40.	1.1	47
18	Trastuzumab-based combination therapy for breast cancer. <i>Expert Opinion on Pharmacotherapy</i> , 2004, 5, 81-96.	0.9	43

#	ARTICLE	IF	CITATIONS
19	Potential biomarkers of long-term benefit from single-agent trastuzumab or lapatinib in HER2-positive metastatic breast cancer. <i>Molecular Oncology</i> , 2014, 8, 20-26.	2.1	37
20	CAR-Based Strategies beyond T Lymphocytes: Integrative Opportunities for Cancer Adoptive Immunotherapy. <i>International Journal of Molecular Sciences</i> , 2019, 20, 2839.	1.8	34
21	Adoptive immunotherapy against ovarian cancer. <i>Journal of Ovarian Research</i> , 2016, 9, 30.	1.3	33
22	Buparlisib, an oral pan-PI3K inhibitor for the treatment of breast cancer. <i>Expert Opinion on Investigational Drugs</i> , 2015, 24, 421-431.	1.9	29
23	Immunotherapy in cervix cancer. <i>Cancer Treatment Reviews</i> , 2020, 90, 102088.	3.4	28
24	Brain Metastases from Ovarian Cancer: Current Evidence in Diagnosis, Treatment, and Prognosis. <i>Cancers</i> , 2020, 12, 2156.	1.7	27
25	Retrospective Evaluation of Clinical Outcomes in Patients with HER2-Positive Advanced Breast Cancer Progressing on Trastuzumab-Based Therapy in the Pre-Lapatinib Era. <i>Clinical Breast Cancer</i> , 2008, 8, 436-442.	1.1	25
26	Role of Cyclin-Dependent Kinase Inhibitors in Endometrial Cancer. <i>International Journal of Molecular Sciences</i> , 2019, 20, 2353.	1.8	24
27	A predictive score for optimal cytoreduction at interval debulking surgery in epithelial ovarian cancer: a two-centers experience. <i>Journal of Ovarian Research</i> , 2018, 11, 42.	1.3	21
28	Omission of Axillary Dissection after a Positive Sentinel Node Dissection may Influence Adjuvant Chemotherapy Indications in Operable Breast Cancer Patients. <i>Annals of Surgical Oncology</i> , 2012, 19, 3755-3761.	0.7	20
29	TOP2A as marker of response to pegylated liposomal doxorubicin (PLD) in epithelial ovarian cancers. <i>Journal of Ovarian Research</i> , 2019, 12, 17.	1.3	20
30	Impact of COVID-19 in gynecologic oncology: a Nationwide Italian Survey of the SIGO and MITO groups. <i>Journal of Gynecologic Oncology</i> , 2020, 31, e92.	1.0	20
31	The MITO CERV-2 trial: A randomized phase II study of cetuximab plus carboplatin and paclitaxel, in advanced or recurrent cervical cancer. <i>Gynecologic Oncology</i> , 2019, 153, 535-540.	0.6	19
32	Recent advances in the development of breast cancer vaccines. <i>Breast Cancer: Targets and Therapy</i> , 2014, 6, 159.	1.0	18
33	Clinical Implications of DNA Repair Defects in High-Grade Serous Ovarian Carcinomas. <i>Cancers</i> , 2020, 12, 1315.	1.7	18
34	Xenopatients show the need for precision medicine approach to chemotherapy in ovarian cancer. <i>Oncotarget</i> , 2016, 7, 26181-26191.	0.8	15
35	Immunotherapy for Cervical Cancer: Are We Ready for Prime Time?. <i>International Journal of Molecular Sciences</i> , 2022, 23, 3559.	1.8	15
36	Ovarian Cancer Cells in Ascites Form Aggregates That Display a Hybrid Epithelial-Mesenchymal Phenotype and Allows Survival and Proliferation of Metastasizing Cells. <i>International Journal of Molecular Sciences</i> , 2022, 23, 833.	1.8	14

#	ARTICLE	IF	CITATIONS
37	Trastuzumab-Related Cardiotoxicity in the Herceptin Adjuvant Trial. <i>Journal of Clinical Oncology</i> , 2008, 26, 2052-2053.	0.8	13
38	Androgen receptor status predicts development of brain metastases in ovarian cancers. <i>Oncotarget</i> , 2017, 8, 41143-41153.	0.8	13
39	Potential of afatinib in the treatment of patients with HER2-positive breast cancer. <i>Breast Cancer: Targets and Therapy</i> , 2012, 4, 131.	1.0	12
40	A Retrospective Analysis of the Activity and Safety of Oral Etoposide in Heavily Pretreated Metastatic Breast Cancer Patients. <i>Breast Journal</i> , 2015, 21, 241-245.	0.4	12
41	Trastuzumab Treatment in Breast Cancer. <i>New England Journal of Medicine</i> , 2006, 354, 2186-2186.	13.9	11
42	Hitting multiple targets in HER2-positive breast cancer: proof of principle or therapeutic opportunity?. <i>Expert Opinion on Pharmacotherapy</i> , 2011, 12, 549-565.	0.9	9
43	New and developing chemical pharmacotherapy for treating hormone receptor-positive/HER2-negative breast cancer. <i>Expert Opinion on Pharmacotherapy</i> , 2016, 17, 2179-2189.	0.9	9
44	Veliparib: a new therapeutic option in ovarian cancer?. <i>Future Oncology</i> , 2019, 15, 1975-1987.	1.1	9
45	Characteristics and outcome of BRCA mutated epithelial ovarian cancer patients in Italy: A retrospective multicenter study (MITO 21). <i>Gynecologic Oncology</i> , 2021, 161, 755-761.	0.6	9
46	The Role of PARP Inhibitors in the Ovarian Cancer Microenvironment: Moving Forward From Synthetic Lethality. <i>Frontiers in Oncology</i> , 2021, 11, 689829.	1.3	9
47	Vinorelbine-based salvage therapy in HER2-positive metastatic breast cancer patients progressing during trastuzumab-containing regimens: a retrospective study. <i>BMC Cancer</i> , 2008, 8, 209.	1.1	8
48	Role of trastuzumab in the management of HER2-positive metastatic breast cancer. <i>Breast Cancer: Targets and Therapy</i> , 2010, 2, 93.	1.0	8
49	Underuse of Anthracyclines in Women with HER-2+ Advanced Breast Cancer. <i>Oncologist</i> , 2010, 15, 665-672.	1.9	8
50	p130Cas scaffold protein regulates ErbB2 stability by altering breast cancer cell sensitivity to autophagy. <i>Oncotarget</i> , 2016, 7, 4442-4453.	0.8	8
51	From Uterus to Brain: An Update on Epidemiology, Clinical Features, and Treatment of Brain Metastases From Gestational Trophoblastic Neoplasia. <i>Frontiers in Oncology</i> , 2022, 12, 859071.	1.3	8
52	PIK3R1W624R Is an Actionable Mutation in High Grade Serous Ovarian Carcinoma. <i>Cells</i> , 2020, 9, 442.	1.8	7
53	Current status and future perspectives in the endocrine treatment of postmenopausal, hormone receptor-positive metastatic breast cancer. <i>Expert Opinion on Pharmacotherapy</i> , 2012, 13, 2143-2156.	0.9	6
54	Cytoreductive Surgery for Heavily Pre-Treated, Platinum-Resistant Epithelial Ovarian Carcinoma: A Two-Center Retrospective Experience. <i>Cancers</i> , 2020, 12, 2239.	1.7	6

#	ARTICLE	IF	CITATIONS
55	Validation of Androgen Receptor loss as a risk factor for the development of brain metastases from ovarian cancers. <i>Journal of Ovarian Research</i> , 2020, 13, 53.	1.3	6
56	SIENDO/ENGOT-EN5/GOG-3055: A randomized phase 3 trial of maintenance selinexor versus placebo after combination platinum-based chemotherapy in advanced or recurrent endometrial cancer.. <i>Journal of Clinical Oncology</i> , 2021, 39, TPS5610-TPS5610.	0.8	6
57	Controversies in breast cancer: adjuvant and neoadjuvant therapy. <i>Expert Opinion on Pharmacotherapy</i> , 2005, 6, 1055-1072.	0.9	5
58	Trastuzumab Beyond Disease Progression: Case Closed?. <i>Journal of Clinical Oncology</i> , 2009, 27, e121-e122.	0.8	5
59	Reprogramming T-cells for adoptive immunotherapy of ovarian cancer. <i>Expert Opinion on Biological Therapy</i> , 2018, 18, 359-367.	1.4	5
60	A fully virtual and nationwide molecular tumor board for gynecologic cancer patients: the virtual experience of the MITO cooperative group. <i>International Journal of Gynecological Cancer</i> , 2022, 32, 1205-1207.	1.2	5
61	Modeling ErbB2-p130Cas interaction to design new potential anticancer agents. <i>Scientific Reports</i> , 2019, 9, 3089.	1.6	4
62	Cytoreductive surgery followed by chemotherapy and olaparib maintenance in BRCA 1/2 mutated recurrent ovarian cancer: a retrospective MITO group study. <i>International Journal of Gynecological Cancer</i> , 2021, 31, ijgc-2020-002343.	1.2	4
63	Biomarkers of Central Nervous System Involvement from Epithelial Ovarian Cancer. <i>Cells</i> , 2021, 10, 3408.	1.8	4
64	Women With Synchronous or Metachronous Lung and Ovarian Cancer: A Multi-Institutional Report. <i>In Vivo</i> , 2019, 33, 2021-2026.	0.6	3
65	Impact of COVID-19 on medical treatment patterns in gynecologic oncology: a MITO group survey. <i>International Journal of Gynecological Cancer</i> , 2021, 31, 1363-1368.	1.2	3
66	Long-lasting, irreversible and late-onset immune-related adverse events (irAEs) from immune checkpoint inhibitors (ICIs): A real-world data analysis.. <i>Journal of Clinical Oncology</i> , 2020, 38, e15095-e15095.	0.8	3
67	Trastuzumab Beyond Progression in Retrospective Analyses: An Issue of Equal Opportunities. <i>Oncologist</i> , 2011, 16, 534-536.	1.9	1
68	Is there a role for immunotherapy in ovarian cancer?. <i>Annals of Translational Medicine</i> , 2019, 7, S276-S276.	0.7	1
69	Translational Research in Ovarian Cancer. <i>Cancers</i> , 2020, 12, 3676.	1.7	1
70	Cancer Cells Haploinsufficient for ATM Are Sensitized to PARP Inhibitors by MET Inhibition. <i>International Journal of Molecular Sciences</i> , 2022, 23, 5770.	1.8	1
71	Recent advances in the medical management of breast cancer: highlights from the 29th San Antonio Breast Cancer Conference. <i>Expert Opinion on Pharmacotherapy</i> , 2007, 8, 1179-1188.	0.9	0
72	Trastuzumab in the adjuvant setting: a practical review. <i>Therapy: Open Access in Clinical Medicine</i> , 2011, 8, 161-177.	0.2	0

#	ARTICLE	IF	CITATIONS
73	Are cyclin-dependent kinases 4/6 inhibitors ready for prime time in estrogen-receptor positive metastatic breast cancer?. <i>Translational Cancer Research</i> , 2017, 6, S197-S200.	0.4	0